News

Sufjan Stevens Shares Rare Update on Health amid Guillain-Barré Syndrome Diagnosis: 'I’m in a State of Repair and Survival'
The indie singer-songwriter announced his diagnosis in 2023 with a photo of himself in a wheelchair Sufjan Stevens gave a ...
Medscape8d
Guillain-Barré Syndrome: When to Suspect, What to Rule Out
The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain-Barré syndrome (GBS), which ...
Nasdaq2d
Annexon, Inc. Presents Positive Real-World Evidence for Tanruprubart in Guillain-Barré Syndrome at 2025 PNS Annual Meeting
The oral presentation highlighted the benefits of tanruprubart in improving patient outcomes compared to current standard treatments for Guillain-Barré Syndrome (GBS), which lacks FDA-approved ...
Investing2d
Annexon reports promising Guillain-Barré treatment results
The company’s lead investigational therapy, tanruprubart, demonstrated significant benefits over current standard care for Guillain-Barré Syndrome (GBS), a rare autoimmune disorder. At the ...
McKnight's Long-Term Care News9d
RSV vaccines protect older adults with 75 percent effectiveness, study finds
A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...
The Bakersfield Californian12d
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First ...
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compar ...
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...